Taking stock of the drug industry, from the lab to the medicine chest

September 27, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy Deb Jenssen Dispute over Duchenne gene therapy highlights thorny access issues Elevidys, a gene therapy developed by Sarepta Therapeutics, has received FDA approval. But insurers are not always quick to provide coverage By Andrew Joseph STAT+ | Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Market analysts have estimated that the new COPD indication could bring in more than $1 billion in additional annual revenue for Dupixent By Jonathan Wosen STAT+ | FDA approves schizophrenia drug that could alter how disorder is treated Cobenfy works by stimulating a pair of muscarinic receptors in the brain, that, in turn, control the release of acetylcholine.  By Adam Feuerstein Adobe STAT+ | Cassava Sciences and former execs, facing SEC charges for misleading claims, agree to fines Cassava was charged Thursday by the SEC with making misleading claims in 2020 about trials for its Alzheimer's drug, and agreed to pay fines. By Jonathan Wosen Sickle cell community scrambles to find safe plan after a drug is pulled from the market Everyone was caught between two possibilities: Taking the drug might put patients at risk, but abruptly stopping the drug could put patients at risk, too. By Eric Boodman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser